FDA Drug Trials Snapshots: Lucemyra

The U.S. Food and Drug Administration (FDA) released this document on May 16, 2018. The document presents research the FDA considered before it approved Lucemyra (lofexidine hydrochloride), a non-opioid medication for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids Lucemyra is manufactured and marketed by US WorldMeds . . .